Literature DB >> 21997392

APOL1 localization in normal kidney and nondiabetic kidney disease.

Sethu M Madhavan1, John F O'Toole, Martha Konieczkowski, Santhi Ganesan, Leslie A Bruggeman, John R Sedor.   

Abstract

In patients of African ancestry, genetic variants in APOL1, which encodes apolipoprotein L1, associate with the nondiabetic kidney diseases, focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy (HIVAN), and hypertensive nephropathy. Understanding the renal localization of APOL1 may provide clues that will ultimately help elucidate the mechanisms by which APOL1 variants promote nephropathy. Here, we used immunohistology to examine APOL1 localization in normal human kidney sections and in biopsies demonstrating either FSGS (n = 8) or HIVAN (n = 2). Within normal glomeruli, APOL1 only localized to podocytes. Compared with normal glomeruli, fewer cells stained for APOL1 in FSGS and HIVAN glomeruli, even when expression of the podocyte markers GLEPP1 and synaptopodin appeared normal. APOL1 localized to proximal tubular epithelia in normal kidneys, FSGS, and HIVAN. We detected APOL1 in the arteriolar endothelium of normal and diseased kidney sections. Unexpectedly, in both FSGS and HIVAN but not normal kidneys, the media of medium artery and arterioles contained a subset of α-smooth muscle actin-positive cells that stained for APOL1. Comparing the renal distribution of APOL1 in nondiabetic kidney disease to normal kidney suggests that a previously unrecognized arteriopathy may contribute to disease pathogenesis in patients of African ancestry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997392      PMCID: PMC3231786          DOI: 10.1681/ASN.2011010069

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  34 in total

1.  Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells.

Authors:  May Brundert; Joerg Heeren; Martin Merkel; Antonella Carambia; Johannes Herkel; Peter Groitl; Thomas Dobner; Rajasekhar Ramakrishnan; Kathryn J Moore; Franz Rinninger
Journal:  J Lipid Res       Date:  2011-01-09       Impact factor: 5.922

2.  Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.

Authors:  Christelle Arrondel; Nicolas Vodovar; Bertrand Knebelmann; Jean-Pierre Grünfeld; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

3.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

4.  The human apolipoprotein L gene cluster: identification, classification, and sites of distribution.

Authors:  N M Page; D J Butlin; K Lomthaisong; P J Lowry
Journal:  Genomics       Date:  2001-05-15       Impact factor: 5.736

5.  Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene.

Authors:  P N Duchateau; C R Pullinger; M H Cho; C Eng; J P Kane
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

6.  The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue.

Authors:  Houshang Monajemi; Ruud D Fontijn; Hans Pannekoek; Anton J G Horrevoets
Journal:  Genomics       Date:  2002-04       Impact factor: 5.736

7.  A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus.

Authors:  Manakan B Srichai; Martha Konieczkowski; Aparna Padiyar; David J Konieczkowski; Amitava Mukherjee; Patrick S Hayden; Sweta Kamat; M Ashraf El-Meanawy; Shenaz Khan; Peter Mundel; Sean Bong Lee; Leslie A Bruggeman; Jeffrey R Schelling; John R Sedor
Journal:  J Biol Chem       Date:  2004-01-20       Impact factor: 5.157

Review 8.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease.

Authors:  Gary K Owens; Meena S Kumar; Brian R Wamhoff
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

9.  Hypertensive nephrosclerosis in African Americans versus Caucasians.

Authors:  Carmelita Marcantoni; Li-Jun Ma; Charles Federspiel; Agnes B Fogo
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

10.  Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome).

Authors:  Gian Marco Ghiggeri; Gianluca Caridi; Umberto Magrini; Adalberto Sessa; Anna Savoia; Marco Seri; Alessandro Pecci; Roberta Romagnoli; Simone Gangarossa; Patrizia Noris; Saverio Sartore; Vittorio Necchi; Roberto Ravazzolo; Carlo L Balduini
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

View more
  132 in total

1.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

2.  APOL1 variants associate with increased risk of CKD among African Americans.

Authors:  Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

Review 3.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

4.  APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Laura Barisoni; David B Thomas; Santhi Ganesan; Leslie A Bruggeman; Matthias Buck; John R Sedor
Journal:  JCI Insight       Date:  2017-07-20

Review 5.  Genetic causes of proteinuria and nephrotic syndrome: impact on podocyte pathobiology.

Authors:  Oleh Akchurin; Kimberly J Reidy
Journal:  Pediatr Nephrol       Date:  2014-03-02       Impact factor: 3.714

6.  JC viruria and kidney disease in APOL1 risk genotype individuals: is this a clue to a gene × environment interaction?

Authors:  Jeffrey B Kopp
Journal:  Kidney Int       Date:  2013-12       Impact factor: 10.612

7.  Haemophagocytic lymphohistiocytosis with collapsing lupus podocytopathy as an unusual manifestation of systemic lupus erythematosus with APOL1 double-risk alleles.

Authors:  Bhavin Chokshi; Vivette D'Agati; Lilian Bizzocchi; Beverly Johnson; Barbara Mendez; Belinda Jim
Journal:  BMJ Case Rep       Date:  2019-01-14

8.  An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.

Authors:  DengFeng Li; James A Snipes; Mariana Murea; Anthony J A Molina; Jasmin Divers; Barry I Freedman; Lijun Ma; Snezana Petrovic
Journal:  Am J Nephrol       Date:  2020-08-31       Impact factor: 3.754

Review 9.  Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.

Authors:  J L Pirkle; B I Freedman
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

Review 10.  New insights on the risk for cardiovascular disease in African Americans: the role of added sugars.

Authors:  Karim R Saab; Jessica Kendrick; Joseph M Yracheta; Miguel A Lanaspa; Maisha Pollard; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.